PureTech Health (PRTC) Jefferies London Healthcare Conference 2024 summary

Key achievements and business model

• Achieved major milestones, including the $14 billion acquisition of Karuna Therapeutics and approval of Cobenfy for schizophrenia.

• Launched Seaport Therapeutics, raising $325 million for neuropsychiatric programs.

• Operates a hub-and-spoke R&D model, spinning out programs as independent entities to attract outside capital.

• Maintains equity, milestone, and royalty interests in spun-out entities, with 80% clinical trial success rate over 15 years.

• Monetized royalty stakes and equity, generating significant self-funding for ongoing R&D.

Pipeline and clinical progress

• LYT-100, a wholly owned asset, is in phase 2b trials for idiopathic pulmonary fibrosis (IPF), with data expected by year-end.

• LYT-200, an oncology program, is in phase 1b for AML and head and neck cancer, with data to be presented in December.

• Vedanta, a founded entity, is in phase 3 for C. difficile infection.

• Seaport Therapeutics, based on the Glyph platform, was spun out after early validation and significant investment.

• Multiple programs in the pipeline provide risk mitigation and ongoing catalysts.

Financial position and capital allocation

• Reported $400 million in cash as of June, with additional inflows expected from future monetizations.

• Completed a $100 million tender offer to provide shareholder liquidity and reduce outstanding shares.

• Allocates capital to existing programs, support for founded entities, future innovation, and tax obligations.

• Maintains at least three years of operating cash, with current balance extending to 2027.

• Reinvests proceeds from monetizations into R&D and shareholder returns.